Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05934903 · ClinicalTrials.gov registry record · NA
Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus
A NA study, sponsored by Yale University.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT05934903 is a NA study that was terminated before completion, run by Yale University. The registered enrollment target is 4 participants.
The verdict
NCT05934903, a NA study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Status epilepticus, or recurrent seizures without return to baseline, is a neurologic emergency. Refractory status epilepticus occurs when seizures are resistant to multiple first line anti-seizure medications. The ability to quickly stop seizures is paramount. Transcranial direct current simulation is a non-invasive, easily administered therapy that can potentially help reduce seizure burden. The goal of this feasibility study is to assess the ability of the study site to enroll patients admitted with refractory seizures or those with abnormal brain wave patterns to take part in a study looking to use transcranial direct current stimulation as an adjunctive treatment. The main questions it aims to answer are: * What is the recruitment capability of the study site? * How well can the study site adhere to study protocol? * Are there any adverse effects of using the transcranial direct current stimulation device? * How do patients' brain wave studies respond to the stimulation? Participants will be asked to consider joining the study. Once joined, researchers will randomly assign participants to compare transcranial stimulation versus sham stimulation to see if this will affect the participant's brain wave patterns.
Interventions
- DEVICE Transcranial Direct Current Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05934903
The ClinicalTrials.gov registry entry for NCT05934903 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transcranial Direct Current Stimulation is the first listed.
NCT05934903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05934903 about?
NCT05934903 is a clinical study titled "Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus". Status epilepticus, or recurrent seizures without return to baseline, is a neurologic emergency. Refractory status epilepticus occurs when seizures are resistant to multiple first line anti-seizure medications. The ability to quickly stop seizures is paramount. Transcranial direct current simulation...
What is the current status of trial NCT05934903?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2023-08-31. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT05934903?
The interventions under investigation include: Transcranial Direct Current Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05934903?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.